Literature DB >> 15285778

Dejerine-Sottas' neuropathy caused by the missense mutation PMP22 Ser72Leu.

W Marques1, J M Pina Neto, A A Barreira.   

Abstract

OBJECTIVE: To describe a patient with the Dejerine-Sottas' syndrome due to a de novo Ser72Leu amino acid substitution in the PMP22 protein and summarize the phenotype associated with this frequent mutation. CASE REPORT: The proband has a medical history of early onset, severe, and progressive demyelinating neuropathy, accompanied by mild ptosis and limitations of eye movements. Ulnar nerve motor conduction velocities were extremely reduced (2.6 and 2.2 m/s), and the sural nerve biopsy showed onion bulbs and thinly myelinated axons. Duplication of chromosome 17p11.2 was ruled out, and the Ser72Leu substitution was found upon sequencing the PMP22 gene.
CONCLUSION: The Ser72Leu substitution is being confirmed as the most frequent point mutation in the PMP22 gene. This 'hot spot' should be considered in the strategy of looking for point mutations in the hereditary demyelinating neuropathies.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15285778     DOI: 10.1111/j.1600-0404.2004.00295.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  3 in total

1.  Compound Charcot-Marie-Tooth disease may determine unusual and milder phenotypes.

Authors:  Silmara P Gouvea; Vinícius H S Borghetti; Keity C Bueno; Adriana B Genari; Charles M Lourenço; Claudia Sobreira; Amilton A Barreira; Wilson Marques
Journal:  Neurogenetics       Date:  2009-08-25       Impact factor: 2.660

Review 2.  New evidence for secondary axonal degeneration in demyelinating neuropathies.

Authors:  Kathryn R Moss; Taylor S Bopp; Anna E Johnson; Ahmet Höke
Journal:  Neurosci Lett       Date:  2020-12-24       Impact factor: 3.046

Review 3.  Comparative genetic analysis: the utility of mouse genetic systems for studying human monogenic disease.

Authors:  Peter L Oliver; Emmanuelle Bitoun; Kay E Davies
Journal:  Mamm Genome       Date:  2007-05-21       Impact factor: 2.957

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.